<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932916</url>
  </required_header>
  <id_info>
    <org_study_id>DON101-CTP</org_study_id>
    <nct_id>NCT03932916</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects</brief_title>
  <official_title>Evaluation of Safety and Pharmacokinetic Profiles of a Single-dose HHT201 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Synergy Pharmaceutical Sciences Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Huahai Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201&#xD;
      in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to evaluate the safety, pharmacokinetics and to determine the potential dose&#xD;
      limiting toxicity of HHT201 in healthy subjects between the ages of 20-59, 6 in 17mg dose&#xD;
      group and 20 in 34mg dose group. Another 12 subjects will be administered a tablet of 5mg&#xD;
      Donepezil Hydrochloride to get the PK profile of Donepezil as reference. Eligible subjects&#xD;
      will be accepted into the protocol after review and providing voluntary written informed&#xD;
      consent forms and completion of a comprehensive medical, physical examination, and routine&#xD;
      laboratory assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Actual">September 11, 2020</completion_date>
  <primary_completion_date type="Actual">August 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Donepezil</measure>
    <time_frame>Blood samples collected over a 35 days period</time_frame>
    <description>Maximum observed concentration of drug substance in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Donepezil</measure>
    <time_frame>Blood samples collected over a 35 days period</time_frame>
    <description>Time when the maximum concentration is acheived</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Donepezil</measure>
    <time_frame>Blood samples collected over a 35 days period</time_frame>
    <description>Area under the concentration-time curve from time zero to time of last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of Donepezil</measure>
    <time_frame>Blood samples collected over a 35 days period</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Donepezil</measure>
    <time_frame>Blood samples collected over a 35 days period</time_frame>
    <description>The time when the concentraion of the drug eliminated to half of the initial.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>AD</condition>
  <arm_group>
    <arm_group_label>experimental group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HHT201 17mg injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HHT201 34mg injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donepezil Hydrochloride oral tablet 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Pamoate for Injection 17mg</intervention_name>
    <description>A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.</description>
    <arm_group_label>experimental group 1</arm_group_label>
    <other_name>HHT201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Pamoate for Injection 34mg</intervention_name>
    <description>A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.</description>
    <arm_group_label>experimental group 2</arm_group_label>
    <other_name>HHT201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Hydrochloride 5mg</intervention_name>
    <description>A tablet of 5mg Donepezil Hydrochloride will be administered once.</description>
    <arm_group_label>experimental group 3</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chinese healthy subjects, male or female&#xD;
&#xD;
          -  between the ages of 20 and 60 years&#xD;
&#xD;
          -  A body mass index (BMI), calculated as weight in kg/(height in m)², from 19 to 28&#xD;
             kg/m², and female weight≥45kg, male weight≥50kg&#xD;
&#xD;
          -  Able to provide written informed consent forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,&#xD;
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,&#xD;
             immunologic, lipid metabolism disorders&#xD;
&#xD;
          2. Resting pulse rate &lt;55/min or &gt;100/min; Sitting systolic blood pressure &lt;90mmHg or&#xD;
             &gt;140mmHg, diastolic blood pressure &lt;60mmHg or &gt;90mmHg&#xD;
&#xD;
          3. ALT or Cr, BUN exceeding the upper limit of normal value; test results of urine&#xD;
             protein was &quot;++&quot;&#xD;
&#xD;
          4. Clinically significant ECG abnormalities in screening or baseline, such as male QTc&#xD;
             interval ≥450ms and female QTc interval ≥470ms, and were considered inappropriate for&#xD;
             inclusion by the researchers&#xD;
&#xD;
          5. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg), or hepatitis C antibody&#xD;
&#xD;
          6. History or presence of drug or alcohol abuse&#xD;
&#xD;
          7. Positive pregnancy test result, or plan to be pregnant if female&#xD;
&#xD;
          8. An unwillingness or inability to comply with food and beverage restrictions within 24&#xD;
             hours prior to dosing&#xD;
&#xD;
          9. Participation in any other investigational drug trial within 30 days prior to&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai mental health center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

